Social Security Fund favors the pharmaceutical sector, and these pharmaceutical companies are included in the list of heavy stocks

Pharmaceutical Network Pharmaceutical Stock Market : With the disclosure of the 2019 annual report of listed companies, the position of the social security fund, which is regarded as a "wind vane" of the market, has recently surfacedOf the 17 listed companies that have emerged as social security funds, 13 have been increased or new, with pharmaceuticals and technology being more widely distributed in the industry
It is understood that as of March 10, among the listed companies that have disclosed their 2019 annual reports, the 17 listed companies have a social security fund among the top 10 outstanding shareholders, with a total shareholding of 305 million shares, corresponding to a market value of 6.313 billion yuanFrom the 17 stocks belong to the industry, the social security fund positions concentrated in science and technology, medicine and other industries, in addition, banking, education, chemical, consumer and other industries also have a layoutIn the pharmaceutical field, such as ShandaHuat's shareholding ratio is the first, Haixiang Pharmaceuticals has obtained a certain amount of increased positions, tonghe pharmaceutical industry new into the social security fund shares
ShandaHuat Social Security Fund has 1 home, the social security fund holdings of 1061.95 million shares, unchanged month-on-month, accounting for 4.55% of the shares in circulation
It is understood that Shandong University and other universities and research institutes for technology, to "commit to the water clearer, bluer sky, more beautiful environment, human healthier cause" for the enterprise mission, forming an environmental protection, medicine-led, electronic information, new materials, education, property and other multi-industry development pattern
According to the 2019 annual report released by ShandaHuat, in 2019, ShandaHuaat achieved operating income of 1.8 billion yuan, up 17.93 percent year-on-year, and net profit attributable to shareholders of listed companies was 204 million yuan, up 57.50 percent year-on-year
Haixiang Pharmaceuticals, the number of social security funds, the social security fund holdings of 100.00 million shares, an increase of 11.11% month-on-month, accounting for 0.62% of the shares in circulation
Haixiang Pharmaceuticals is a listed company that produces specialty raw materials, preparations and fine chemicals, dyes and dyes intermediatesThe main products are antibiotics, cardiovascular, sugar-lowering and other raw materials, refined chemicals, preparations, dyes and intermediates, pharmaceutical products more than 70% of exports, of which klinmycin series production in a leading position
According to Haixiang Pharmaceuticals' 2019 annual report, the company achieved operating income of RMB2,941 million in 2019, up 8.20% YoY, and achieved a net profit attributable to shareholders of listed companies of RMB771 million, up 27.40% YoY
The main business of the same-drug industry is the research and development, production and sales of chemical raw materials and pharmaceutical intermediates, the main product direction is the characteristic chemical raw materials and intermediates, patented api entitiesIn the development process has formed a "serious and rigorous, honest and trustworthy, unity and cooperation, initiative to promote" as the core values of the corporate culture
According to the 2019 annual report of Tonghe PharmaceuticalsThe annual report shows that the company achieved operating income of RMB413 million in 2019, up 54.63% YoY, and net profit attributable to shareholders of listed companies was RMB48.3093 million, up 96.93% YoY At the same time, the net profit attributable to shareholders of listed companies is expected to be RMB983.51 million - RMB11.1763 million in January-March 2020, up 120% -150% YoY.